MX2020009720A - Virus recombinante capaz de expresar de manera estable proteinas objetivo. - Google Patents
Virus recombinante capaz de expresar de manera estable proteinas objetivo.Info
- Publication number
- MX2020009720A MX2020009720A MX2020009720A MX2020009720A MX2020009720A MX 2020009720 A MX2020009720 A MX 2020009720A MX 2020009720 A MX2020009720 A MX 2020009720A MX 2020009720 A MX2020009720 A MX 2020009720A MX 2020009720 A MX2020009720 A MX 2020009720A
- Authority
- MX
- Mexico
- Prior art keywords
- recombinant virus
- target proteins
- stably expressing
- expressing target
- virus capable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018079410 | 2018-03-19 | ||
| PCT/CN2019/078057 WO2019179345A1 (en) | 2018-03-19 | 2019-03-14 | Recombinant virus capable of stably expressing target proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020009720A true MX2020009720A (es) | 2021-01-08 |
Family
ID=67988104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020009720A MX2020009720A (es) | 2018-03-19 | 2019-03-14 | Virus recombinante capaz de expresar de manera estable proteinas objetivo. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11904010B2 (enExample) |
| EP (1) | EP3768831A4 (enExample) |
| JP (1) | JP7387623B2 (enExample) |
| KR (1) | KR102785418B1 (enExample) |
| CN (1) | CN111902535B (enExample) |
| AU (1) | AU2019237413C1 (enExample) |
| CA (1) | CA3094416A1 (enExample) |
| MX (1) | MX2020009720A (enExample) |
| WO (1) | WO2019179345A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020009720A (es) * | 2018-03-19 | 2021-01-08 | Boehringer Ingelheim Vetmedica China Co Ltd | Virus recombinante capaz de expresar de manera estable proteinas objetivo. |
| EP4065709A4 (en) * | 2019-11-25 | 2023-11-29 | Baylor College of Medicine | SELECTIVE EXPANSION OF GENE-TARGETED CELLS |
| CN112430625B (zh) * | 2020-11-23 | 2022-08-05 | 武汉枢密脑科学技术有限公司 | 含有变异猪伪狂犬病病毒gD蛋白基因的重组腺相关病毒转移载体、病毒及其制备和应用 |
| WO2026162693A1 (en) * | 2025-02-01 | 2026-08-06 | Intervet International B.V. | A method to preserve virus like particles of foot and mouth disease virus |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4110962A1 (de) * | 1991-04-05 | 1992-10-08 | Bayer Ag | Equine herpesviren (ehv), die fremd-dna enthalten, verfahren zu ihrer herstellung und ihre verwendung in impfstoffen |
| MX9206981A (es) | 1991-12-06 | 1994-08-31 | Whitehead Biomedical Inst | Vacunas de recombinantes y metodo para producirlas. |
| GB9927353D0 (en) * | 1999-11-19 | 2000-01-19 | Cantab Pharma Res | Virus preparation and use |
| CN101595228A (zh) * | 2005-07-21 | 2009-12-02 | 艾博特公司 | 包括sorf构建体的多基因表达和使用多蛋白、前体蛋白和蛋白酶解的方法 |
| WO2007059461A2 (en) * | 2005-11-10 | 2007-05-24 | Genvec, Inc. | Adenoviral vector-based foot-and-mouth disease vaccine |
| CN101444622A (zh) * | 2008-06-06 | 2009-06-03 | 中国人民解放军军事医学科学院军事兽医研究所 | 以猪伪狂犬病病毒为载体的日本血吸虫基因重组活疫苗生产工艺及制品 |
| RU2546247C2 (ru) | 2013-06-06 | 2015-04-10 | Автономная некоммерческая организация "Научно-исследовательский институт диагностики и профилактики болезней человека и животных" (АНО "НИИ ДПБ") | Вакцина против чумы, аденовирусных инфекций, парвовирусного и коронавирусного энтеритов, лептоспироза и бешенства собак |
| JP6797206B2 (ja) * | 2015-11-23 | 2020-12-09 | ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド | Ｆｍｄｖ及びｅ２融合タンパク質並びにその使用 |
| CN107723281B (zh) | 2017-09-09 | 2021-02-12 | 中国农业科学院哈尔滨兽医研究所 | 表达猪圆环病毒2型Cap蛋白的重组猪瘟兔化弱毒疫苗株及其应用 |
| MX2020009720A (es) * | 2018-03-19 | 2021-01-08 | Boehringer Ingelheim Vetmedica China Co Ltd | Virus recombinante capaz de expresar de manera estable proteinas objetivo. |
| CA3091954A1 (en) * | 2018-03-19 | 2019-09-26 | Boehringer Ingelheim Vetmedica Gmbh | New ehv with inactivated ul18 and/or ul8 |
-
2019
- 2019-03-14 MX MX2020009720A patent/MX2020009720A/es unknown
- 2019-03-14 JP JP2020551267A patent/JP7387623B2/ja active Active
- 2019-03-14 CN CN201980019886.5A patent/CN111902535B/zh active Active
- 2019-03-14 WO PCT/CN2019/078057 patent/WO2019179345A1/en not_active Ceased
- 2019-03-14 EP EP19770578.3A patent/EP3768831A4/en active Pending
- 2019-03-14 AU AU2019237413A patent/AU2019237413C1/en active Active
- 2019-03-14 US US17/046,210 patent/US11904010B2/en active Active
- 2019-03-14 CA CA3094416A patent/CA3094416A1/en active Pending
- 2019-03-14 KR KR1020207029714A patent/KR102785418B1/ko active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020133457A (ru) | 2022-04-19 |
| KR20200135412A (ko) | 2020-12-02 |
| CN111902535A (zh) | 2020-11-06 |
| US20210353734A1 (en) | 2021-11-18 |
| EP3768831A4 (en) | 2022-01-05 |
| JP7387623B2 (ja) | 2023-11-28 |
| US11904010B2 (en) | 2024-02-20 |
| KR102785418B1 (ko) | 2025-03-26 |
| EP3768831A1 (en) | 2021-01-27 |
| AU2019237413B2 (en) | 2025-08-07 |
| AU2019237413C1 (en) | 2025-10-30 |
| CN111902535B (zh) | 2024-08-27 |
| WO2019179345A1 (en) | 2019-09-26 |
| AU2019237413A1 (en) | 2020-09-24 |
| JP2021518152A (ja) | 2021-08-02 |
| CA3094416A1 (en) | 2019-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021005254A (es) | Produccion recombinante de una preparacion de peptido de colageno y uso de la misma. | |
| EP4389900A3 (en) | Generating mammalian t cell activation inducible synthetic promoters (syn+pro) to improve t cell therapy | |
| PH12019500854A1 (en) | Recombinant vectors expressing antigens of avian influenza virus and uses thereof | |
| PH12019501366A1 (en) | Recombinant hvt vectors expressing multiple antigens of avian pathogens, and vaccines comprising them | |
| MX2024008936A (es) | Proteinas de union a antigeno de baja viscosidad y metodos de prepararlas. | |
| MX380631B (es) | Vectores de adenovirus canino | |
| MX2017005788A (es) | Vacunas terapeuticas contra el vph16. | |
| EA202091259A1 (ru) | Способ получения опикапона и его интермедиатов | |
| MX2017015690A (es) | Anticuerpos dirigidos a la proteina morfogenetica osea 9 (bmp9) y metodos a partir de estos. | |
| MX2021007119A (es) | Metodos para producir anticuerpos heterodimericos. | |
| IL279782B2 (en) | Methods for producing recombinant proteins | |
| MY179251A (en) | Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development | |
| PH12019500903A1 (en) | Isolation of a novel pestivirus causing congenital tremor a | |
| PH12019500557A1 (en) | New ehv insertion site orf70 | |
| MX2020003211A (es) | Proteina de fusion que comprende una porcion de fgf-18. | |
| MX2015013304A (es) | Vacunas de nucleoproteina de la influenza. | |
| MY190102A (en) | Tolerogenic dna vaccine | |
| MX2019007924A (es) | Vacunas contra la influenza. | |
| PH12019500578A1 (en) | New promoters | |
| PH12021553186A1 (en) | Chikungunya vaccine formulations | |
| MX390927B (es) | Partículas semejantes a virus recombinantes que utilizan la proteína gag del virus de inmunodeficiencia bovina. | |
| EP3768831A4 (en) | RECOMBINANT VIRUS FOR STABLE EXPRESSION OF TARGET PROTEINS | |
| MX2019013750A (es) | Un metodo para producir ranibizumab humanizado recombinante replegado. | |
| EA201892385A1 (ru) | Модификация сконструированных полипептидов гемагглютинина вируса гриппа | |
| MY188494A (en) | High-growth enterovirus 71 strains and vaccines |